MedTrace Logo

Comparing a Virtual vs. Face to Face Weight Management Program Using Phentermine for Patients With Overweight or Obesity

NCT04614545 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2022-12-07

Study results available
· View outcomes & findings →

Summary

This study will study the effects associated with the prescription of phentermine in a virtual setting, comparing with prescription of phentermine via a standard face-to-face visit for patients with obesity or overweight.

Conditions

Interventions

DRUG

Phentermine 37.5 Mg

Patients will receive 37.5 mg of phentermine daily for a 12 week duration

BEHAVIORAL

Dietary program

Patients will be able to select either the Mediterranean diet or the Ketogenic diet and will work with a dietician

BEHAVIORAL

Exercise program

Patients will be provided with a personalized exercise program

Sponsors & Collaborators

  • The Cleveland Clinic

    lead OTHER

Principal Investigators

  • Marcio Griebeler, MD · The Cleveland Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2021-08-27
Completion
2022-09-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04614545 on ClinicalTrials.gov